LAB in the 13F filings
Standard Biotools Inc · CUSIP 34385P108
- Quarter end
- 31 Mar 2026
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 12 May 2026
- Managers listing it
- 13
- at least, of 95 tracked, among listed positions
- Comparable managers
- 91
- filed both Q4 2025 and Q1 2026; 1 listed it in both
- Shares listed
- 68,890,945
- combined, among listed positions
- Reported value
- $63m
- combined, at the quarter end
AllianceBernstein LP. Values in this filing are at the previous quarter end's prices; its share count is the quarter end's.
Among the 91 comparable managers: 8 buyers (opened or added shares) and 4 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was -4,158,963.
Managers listing LAB in Q1 2026
13 of 13 holders
Largest increases and reductions, by shares
Increases
- AQR Capital Management LLCexisting position · 933,098 shares now+513,545
- D. E. Shaw & Co.new position · 199,084 shares now+199,084
- Citadel Advisors LLCexisting position · 1,225,310 shares now+148,949
- Invesco Ltdexisting position · 258,344 shares now+71,576
- Susquehanna International Group LLPexisting position · 153,343 shares now+63,409
Reductions
- Millennium Management LLCexisting position · 2,102,015 shares now-1,285,413
- Point72 Asset Management LPexisting position · 44,721 shares now-98,586
New positions and exits
New (1)
- D. E. Shaw & Co.$183k
Exited (2)
- ARK Investment Management LLCwas $3.9m
- Jane Street Group LLCwas $985k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q3 2015 | 1 | $6.5m | n.a. | n.a. |
| Q4 2015 | 1 | $8.6m | n.a. | n.a. |
| Q1 2016 | 2 | $9.9m | n.a. | n.a. |
| Q2 2016 | 3 | $10m | n.a. | n.a. |
| Q3 2016 | 2 | $6.7m | n.a. | n.a. |
| Q4 2016 | 2 | $6.1m | n.a. | n.a. |
| Q1 2017 | 1 | $100k | n.a. | n.a. |
| Q1 2018 | 1 | $873k | n.a. | n.a. |
| Q2 2018 | 2 | $2.0m | n.a. | n.a. |
| Q3 2018 | 4 | $41m | n.a. | n.a. |
| Q4 2018 | 4 | $60m | n.a. | n.a. |
| Q1 2019 | 6 | $101m | n.a. | n.a. |
| Q2 2019 | 5 | $89m | n.a. | n.a. |
| Q3 2019 | 3 | $9.5m | n.a. | n.a. |
| Q4 2019 | 1 | $5.9m | n.a. | n.a. |
| Q1 2020 | 2 | $4.3m | n.a. | n.a. |
| Q2 2020 | 1 | $5.3m | n.a. | n.a. |
| Q3 2020 | 5 | $51m | n.a. | n.a. |
| Q4 2020 | 4 | $13m | n.a. | n.a. |
| Q1 2021 | 1 | $2.2m | n.a. | n.a. |
| Q2 2021 | 1 | $1.2m | n.a. | n.a. |
| Q3 2021 | 1 | $843k | n.a. | n.a. |
| Q4 2021 | 1 | $585k | n.a. | n.a. |
| Q1 2024 | 2 | $194m | 2 | 0 |
| Q2 2024 | 2 | $126m | 0 | 1 |
| Q3 2024 | 2 | $130m | 0 | 1 |
| Q4 2024 | 2 | $108m | 0 | 1 |
| Q1 2025 | 2 | $67m | 1 | 0 |
| Q2 2025 | 2 | $74m | 0 | 1 |
| Q3 2025 | 2 | $80m | 0 | 1 |
| Q4 2025 | 2 | $79m | 7 | 5 |
| Q1 2026 | 1 | $54m | 8 | 4 |
| Q2 2026 | 1 | $48m | 18 | 5 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
LAB and LLY →LAB and JNJ →LAB and VRTX →Choose a stock to compare with LAB →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own LAB, latest filings →Back to the 13F Explorer →